A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041)

• Main Authors: Chiu, J.W, Hotte, S.J, Kollmannsberger, C.K, Renouf, D.J, Cescon, D.W, Hedley, D, Chow, S, Moscow, J, Chen, Z, Perry, M, Diaz-Padilla, I, Tan, D, Hirte, H, McWhirter, E, Chen, H, Siu, L.L, Bedard, P.L
• Other Authors: MEDICINE
• Format: Article
• Published: Springer New York LLC 2020
• Subjects: angiogenic factor; angiopoietin receptor; temsirolimus; thymidine phosphorylase; trebananib; antineoplastic agent; hybrid protein; rapamycin; adult; advanced cancer; aged; anorexia; antineoplastic activity; Article; blood level; cancer fatigue; clinical article; clinical effectiveness; controlled study; drug efficacy; drug mechanism; drug response; drug safety; drug tolerability; edema; female; human; lymphocytopenia; male; maximum plasma concentration; monocyte; mucosa inflammation; multiple cycle treatment; nausea; phase 1 clinical trial; priority journal; protein expression; rash; solid tumor; analogs and derivatives; chemically induced; clinical trial; fatigue; maximum tolerated dose; middle aged; Neoplasms; pathology; treatment outcome; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Edema; Fatigue; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Recombinant Fusion Proteins; Sirolimus; Treatment Outcome
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/179600
• Institution: National University of Singapore

10.1007/s10637-015-0313-8